BioCentury
ARTICLE | Company News

Medicines Co. cuts workforce for Ionsys discontinuation

June 23, 2017 7:09 PM UTC

In an SEC filing, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount by 60 (about 15%) after it withdrew Ionsys fentanyl iontophoretic transdermal system from the U.S. market. At Feb. 27, the company had 410 employees. Last month, the company said in an SEC filing it would seek to partner or divest the product and discontinue commercialization if a deal was not found in 2Q17. The company did not respond to inquiries (see BioCentury, May 29).

Ionsys is a needle-free, patient-controlled, preprogrammed delivery system of fentanyl, a mu opioid receptor (MOR; OPRM1) agonist. ...

BCIQ Company Profiles

The Medicines Co.